One FDA Meeting Killed This Entire Biotech Company

The Science Was Actually Promising

This is what makes the story sting. Pociredir's mechanism was clever and the clinical results were genuinely encouraging.

In sickle cell disease, red blood cells contain a mutant hemoglobin (HbS) that clumps together and deforms the cells into rigid, sickle-shaped discs. Those misshapen cells clog blood vessels, causing excruciating pain crises and organ damage. But there's a workaround: fetal hemoglobin (HbF), the version babies produce in the womb, can block HbS from clumping. Adults still carry the genes for it; they're just switched off.

Pociredir's job was to flip those genes back on by inhibiting EED, which loosened PRC2's grip on a key repressor gene called BCL11A. Less BCL11A means more fetal hemoglobin. It's essentially the same strategy as gene therapies like Casgevy, but in a daily pill instead of a one-time bone marrow procedure.

In the Phase 1b PIONEER trial, patients on the 20 mg dose saw their fetal hemoglobin rise by an average of 9.9 percentage points after just six weeks. Over half of them reached HbF levels above 20%, a threshold that sickle cell literature associates with real clinical benefit. The drug also improved markers of red blood cell destruction, suggesting it was actually reducing the sickling process.

And critically: no new safety signals emerged in pociredir's own clinical data. The cancer concern was inherited from a cousin drug, not earned from its own track record.

Nine People and $333 Million

What's left of Fulcrum is an unusual entity. The company reported roughly $333 million in cash as of March 2026, enough to keep the lights on through 2029 with a skeleton crew. But there's no pipeline left to fund. Pociredir was Fulcrum's only clinical-stage program, and without it, there's nothing to develop.

The company has hired Leerink Partners to run a strategic review. Translation: they're shopping for a buyer, a merger partner, or some creative transaction that salvages value for shareholders. Options on the table include an outright sale, licensing whatever intellectual property remains, or a reverse merger where another biotech essentially absorbs Fulcrum's cash pile and public listing.

Analyst sentiment reflects the wreckage. The consensus rating sits at Hold/Reduce, with one analyst recently cutting their price target to just $3, right around where the stock was already trading. The few higher targets still floating around ($8 to $10) are likely stale numbers from before the world ended for Fulcrum.

A Warning Shot for the Whole Field

Fulcrum's collapse isn't just a company story. It's a signal about how the FDA is thinking about safety in hemoglobinopathy drugs, and the message is: mechanism matters more than your data.

This isn't an isolated case. The agency required dramatically strengthened cancer warnings for Skysona, a gene therapy for a different condition, after the rate of blood cancers in trial participants climbed from 4% to 15% over time. It put clinical holds on gene therapies from REGENXBIO after a brain tumor appeared years after treatment. And it blocked Gilead's cancer immunotherapy program after a mortality imbalance showed up in a pivotal trial.

The pattern is clear: when the FDA identifies a class-level cancer risk, individual drugs get swept up whether or not they've shown problems on their own. For companies developing epigenetic therapies, gene editing tools, or anything that touches the fundamental machinery of gene regulation, the bar for safety evidence is getting higher.

The Brutal Math of Being a One-Trick Pony

Fulcrum joins a growing list of single-program biotechs that went from promising to shell company after a single regulatory blow. RAPT Therapeutics killed its lead program in 2024 after one patient needed a liver transplant. PepGen abandoned its entire Duchenne muscular dystrophy franchise in 2025 after a safety hold combined with disappointing efficacy data.

The lesson keeps repeating itself: when your entire company depends on one drug, a single FDA meeting can be an extinction event. Fulcrum had good science, encouraging data, and a compelling target. None of it mattered once the agency decided the whole drug class was tainted.

Nine employees remain. The strategic review clock is ticking. And $333 million in cash is looking for a new home.

The Pentagon Just Dropped a Bomb on Biotech's Favorite Supplier

The Pentagon just labeled WuXi AppTec a "Chinese military company," and the ripple effects could force hundreds of biotech and pharma companies to rethink how their drugs get made. The world's largest CDMO is now at the center of a geopolitical earthquake.